Pharming, CASI, Kairos Plan Presentations at H.C. Wainwright Conference

Several biopharmaceutical companies are set to present their updates and data at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025. CASI Pharmaceuticals will feature CEO David Cory, highlighting their anti-CD38 monoclonal antibody CID-103, currently in Phase 1/2 trials for immune thrombocytopenic purpura and planning a study in renal allograft antibody-mediated rejection. Pharming Group CEO Fabrice Chouraqui will present on the company's innovative treatments for rare diseases, with a live webcast available and options for one-on-one investor meetings. Kairos Pharma will showcase CEO John Yu's corporate overview and present Phase 1 data on their cancer therapy ENV105 combined with osimertinib for lung cancer, with presentations accessible on-demand and opportunities for investor meetings. These presentations reflect ongoing advancements in therapies for transplant rejection, autoimmune diseases, rare disorders, and cancer, underscoring the companies’ efforts to address unmet medical needs and drug resistance in their respective fields.